Panbela Therapeutics, Inc. (PBLA)

Compare

0.3197

0.0000

(0.00%)

At close: 3:02:13 PM EDT

Panbela Provides Business Update and Reports Q3 2024 Financial Results

MINNEAPOLIS, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended September 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q3 2024 and Recent Highlights: Up to $12.0 million financing commitment secured from strategic i

GlobeNewswire 4 months ago

PBLA
0.00%
Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

MINNEAPOLIS, Oct. 31, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on November 14, 2024, at 4:30 PM Eastern Time to discuss results for its third quarter ended September 30, 2024. Conference Call InformationToll Free: 877-545-0320International: 973-528-0002Participant Access Code: 370494We

GlobeNewswire 4 months ago

PBLA
0.00%
First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

MINNEAPOLIS, Sept. 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced the first patient enrolled in a Phase I dose escalation study to evaluate CPP-1X-S (eflornithine sachets) in STK11 mutant non-small cell lung cancer (NSCLC). The initial goal of the Phase I trial will be to determine the maximum tolerated dose of eflornithine in combinat

GlobeNewswire 6 months ago

PBLA
0.00%
Panbela Provides Business Update and Reports Q2 2024 Financial Results

MINNEAPOLIS, Aug. 13, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended June 30, 2024. As previously announced, management is hosting an earnings call today at 4:30 p.m. ET. Q2 2024 and Recent Highlights: Clinical Phase 3 ASPIRE clinical trial received favorable third indepe

GlobeNewswire 7 months ago

PBLA
0.00%
Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

MINNEAPOLIS, July 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on Aug 13, 2024, at 4:30 PM Eastern Time to discuss results for its second quarter ended June 30, 2024. Conference Call Information Toll Free: 888-506-0062International: 973-528-0011Participant Access Code: 405072Webcast Li

GlobeNewswire 7 months ago

PBLA
0.00%
Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

DSMB Recommends Continuation without Modification for Third TimeSafety Review Included 395 PatientsInterim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low Event Rate Suggests Potential for Prolonged SurvivalRapid Enrollment Positions Company for Enrollment Completion by Q1 2025; Earlier Than Expected MINNEAPOLIS, June 24, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therape

GlobeNewswire 9 months ago

PBLA
0.00%
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):

Evaluation of the Safety and Efficacy of Eflornithine (Difluoromethylornithine, DFMO) in Patients with Gastric Premalignant Conditions in the High Incidence Areas of Latin AmericanMINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announces an oral presentation at the Digestive Disease Week (DDW) conference, which was held May 18-21,

GlobeNewswire 9 months ago

PBLA
0.00%
Panbela Provides Business Update and Reports Q1 2024 Financial Results

MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today provides a business update and reports financial results for the quarter ended March 31, 2024. As previously announced, management is hosting earnings call today at 4:30 p.m. ET. Q1 2024 and recent Highlights: Clinical Announced revised timing for the interim data analysis for its o

GlobeNewswire 10 months ago

PBLA
0.00%
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac

Developed in collaboration with Sanofi.MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced an Issue Notification for the US continuation patent US 11,925,613 B2 and Canadian patent CA 3003149 titled “EFLORNITHINE AND SULINDAC, A FIXED DOSE COMBINATION FORMULATION”. These patents claim a novel composition of a fixed dose combi

GlobeNewswire 10 months ago

PBLA
0.00%
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that it will host a conference call on May 15, 2024, at 4:30 PM Eastern Time to discuss results for its first quarter ended March 31, 2024. Conference Call Information Toll Free: 877-545-0523International: 973-528-0016Participant Access Code: 234396Webcast Lin

GlobeNewswire 10 months ago

PBLA
0.00%
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week

MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announced that an abstract for eflornithine, an inhibitor of polyamine synthesis, has been accepted for an oral presentation at the Digestive Disease Week (DDW) conference, which will be held May 18-21, 2024. The work reflects the Company’s on-going collaboration with Vanderbilt Univ

GlobeNewswire 10 months ago

PBLA
0.00%
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

Trial's lower-than-expected event rate suggests improved survival outcomesMINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that the interim data analysis for its ongoing ASPIRE trial is now expected to be available as soon as Q1 2025. This delay in the projected date for analysis comes as a result of the t

GlobeNewswire 11 months ago

PBLA
0.00%
Panbela Announces Poster Presentation at American Association for Cancer Research:

Ivospemin/doxorubicin combination modulates polyamine metabolism to improve survival in murine ovarian cancer modelsMINNEAPOLIS, April 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA)(“Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer today announces a poster presentation highlighting the results for ivospemin (SBP-101) as a polyamine metabolism modulator in ovarian cancer at the American Associ

GlobeNewswire 11 months ago

PBLA
0.00%
Panbela Announces Transfer to OTCQB Market

MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced that its common stock has been approved for quotation on the OTCQB market. Panbela’s common stock will be eligible for quotation on the OTCQB starting on April 17, 2024, under the symbol “PBLA.” OTCQB is a venture market operated by the OTC Markets Group Inc

GlobeNewswire 11 months ago

PBLA
0.00%

Performance Overview

Return	PBLA	S&P 500 (^GSPC)
YTD	-15.87%	-3.58%
1-Year	-41.87%	+8.94%
3-Year	-100.00%	+24.75%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Panbela Therapeutics, Inc. (PBLA)

Panbela Provides Business Update and Reports Q3 2024 Financial Results

Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

Panbela Provides Business Update and Reports Q2 2024 Financial Results

Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

Panbela Announces Oral Presentation at Digestive Disease Week (DDW):

Panbela Provides Business Update and Reports Q1 2024 Financial Results

Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac

Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week

Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025

Panbela Announces Poster Presentation at American Association for Cancer Research:

Panbela Announces Transfer to OTCQB Market

Performance Overview